Search Results 521-530 of 2962 for 必应搜索引擎留痕咨询邮箱:lgooxc@hotmail.com
Quantifying functional decline for novel clinical trial outcome measure development and guiding clinical care. Participation eligibility. Participant ...
About this study. The purpose of this study is to use body surface gastric mapping (BSGM) and gastroduodenal manometry (GDM) to (1) identify disturbances ...
Review select publications related to research in the Mayo Clinic Hepatobiliary SPORE in Mayo Clinic Comprehensive Cancer Center.
After completing standard-of-care (SOC) CDI antibiotics for their most recent CDI recurrence, patients who meet all eligibility requirements will be randomized ...
Learn about publications and news in Nilufer Ertekin-Taner's Genetics of Alzheimer's Disease and Endophenotypes lab at Mayo Clinic.
Mocetinostat is an orally administered histone deacetylase (HDAC) inhibitor. Azacitidine is a hypomethylating agent (HMA) used to treat MDS. In this study, ...
Early clinical data have demonstrated anti-tumor activity with ulixertinib treatment and have identified specific groups of patients for whom additional ...
Immuno-Epigenetics: William A. · Immunometabolism and Cancer Immunology: Marion R. · Infection and Immunity: Raymund R. · Infectious Diseases: Robin Patel ...
About this study. The purpose of this study is to determine how polyamine depletion impacts extracellular intratumoral guanidinoacetate abundance.
Bielinski, Suzette J. Ph.D., M.Ed. bielinski.suzette@mayo.edu; Professor of Epidemiology; Publications · Borad, Mitesh J. M.D..
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.